Table Shells

Attachment 2

Table Shells for Analysis

Table 1. Percentage of Investigators receiving each type of funding in the past 10 years and throughout career and primary sources of funding for same time periods

Funding Source	Percentage of Investigators receiving funding Career Last 10 years		Percentage of Investigators receiving primary funding Career Last 10 years
NIEHS
NHLBI
NIAID
NICHD
Other NIH
CDC
AHRQ
FDA
EPA
HUD
NSF
Other US government (not listed above)
Foundations
Industry
University discretionary/ start-up funds
Local, state or regional government
Other

Table 2. Percentage of Investigators receiving specific types of NIH-funding for research

Type of Funding	Percentage of Investigators
Research (e.g., R01, R03, R21)
Program/Center (e.g., M, P and U awards)
Career Development Individual (e.g., K awards; R23, R29)
Fellowships (e.g., F awards)
Institutional Training (e.g., T32)
Technology Development (e.g., SBIR, STTR; R41-44, N43-44, U43-44)

Table 3. Percentage of researchers engaged in basic and applied sciences related to the selected science portfolio by field

Field of Research	Percentage of Investigators
Basic Sciences Biochemistry Biophysics Botany Cellular biology Ecology Environmental Sciences Epigenetics Genetics Immunology Medicine Microbiology Molecular biology Physiology Toxicology Other please specify________
Applied Sciences Clinical Research Public Health Research Health Services Research Intervention Research Program or Policy Research Technology Innovation Translational Research Other please specify________

Table 4. Age distribution of investigators

Age Category	Percentage of Investigators
<30
30-39
40-49
50-59
60+

Table 5. Percentage of investigators by degrees awarded

Degree	Percentage of Investigators
AB, BA, BS, BSc
MA, MS, MHS, MPH, MPA, MED, MSIH
PhD, Sc.D, DSc
MD
Other clinical degree (e.g. DO, DDS, MBBS, RN)
None

Table 6. Distribution of year of highest degree

Year	Percentage of Investigators
1976-1980
1981-1985
1986-1990
1991-1995
1996-2000
2001-2005
2006-

Table 7. Number/Percentage of Research Outputs Produced by Investigators

Research Output			Number of Investigators	Percentage of Projects
Biological Materials		Biological material or application identified or developed as a result of the research study.
Databases, Software, Algorithms		Database resulting from the research study.
		Software resulting from the research study.
		Algorithm resulting from the research study.
License Agreements		License agreement executed for intellectual property generated by the research study.
Measurement Instruments		Measurement instrument developed by the research study.
Research Data (public or restricted)		Research data generated by the research study.
Economic Outcomes		Research study findings result in a cost-effective intervention for a disease, condition, or disorder.
		Research study findings result in enhancement of existing resources and expertise.
		Research study findings result in increased performance, quality, and consistency in the delivery of health care services.
Health Care Outcomes		Research study findings result in clinically effective approach in the management and treatment of a disease, disorder or condition.
Quality of Life		Research study findings leads to enhancement of well-being among community members.

Table 8. Number/Percentage of Knowledge Transfer Outputs Achieved by Investigators

Knowledge Transfer Output			Number of Investigators	Percentage of Projects
Alternative/ Informal Dissemination		Research study is referred to or cited in a blog, tweet, wiki or other alternative mode of dissemination.
		Research study is cited in a presentation, speech or teaching materials.
Biological Materials		Subsequent use of a particular biological material or application of the material generated by the research study in a bench study (basic science) or clinical trial study.
		Clinical data generated in support of marketing a biological material (BLA) generated by the research study.
Clinical Guidelines		The clinical guideline refers to the research study or recommends the study for background readings.
Curriculum Guidelines		The curriculum guideline refers to the research study or recommends the study for background readings.
License Agreements		License agreement granted for use of intellectual property generated by the research study.
Mass Media		Mass media publication refers to the research study.
Material Transfer Agreements (MTA)		MTA executed for transfer of tangible property generated by the research study.
Medical Devices		Clinical trial study testing of a medical device generated by the research study.
		Clinical data generated in support of marketing a medical device (510(k); Investigational Device Exemption, IDE; or Premarket Approval, PMA) generated by the research study.
Meta-Analyses		Research study cited in a meta-analysis.
Pharmaceutical Preparations		Subsequent use of a drug generated by the research study in a bench study (basic science) or clinical trial study.
		Clinical data generated in support of marketing a drug (Investigational New Drug Application, IND; New Drug Application, NDA; Abbreviated New Drug Application, ANDA; or 505(b)(2)) generated by the research study.
Ancillary Research Studies		Ancillary research study generated as a result of the research study.
New Research Studies		New research study generated as a result of the research study.
Subject Headings/ Thesauri		New subject heading or thesauri term or phrase resulting or related to the research study is applied.

Table 9. Career Development Outputs

Table 10. Training Outputs

Table 11. Percentage of investigators that have disseminated research by the following mechanisms

Dissemination mechanism	Percentage of investigators
Published in peer-reviewed journals
Presented at scientific conferences
Participated in grantee meetings
Developed and disseminated curricula
Developed and disseminated interventions
Developed and disseminated research tools and methods
Participated in the development of clinical guidelines for the treatment of asthma
Participated in workshops or trainings disseminating your research
Provided scientific testimony and briefings to legislators
Developed and published websites
Presented research in community forums
Developed fact sheets and pamphlets
Provided information for press releases

Table 12. Nature of investigator personal engagement by type of engagement

	Percentage of Investigators
Group	Share information	Conduct joint projects or activities	Serve on boards or advisory panels	Provide formal testimony	Serve as employee or consultant	No interaction
Other researchers
University administration / program directors
Local, regional or national health officials
Environmental regulators
Food and drug regulators
Legislators and staffers
Business and industry representatives
Housing and urban development agencies
Advocacy groups
Community groups

Table 13. Percentage of Investigators who have applied for patents and commercialized innovation

IP Action	Percentage of Investigators
Patent application
Patent
Nature of patent New drug New use of drug Medical product or device Environmental controls and services New process or procedure New research method New gene
Commercialization of Patent
License Patent
Started spin-off or new company

Table 14. Percentage of investigators who received patents and received support from federal agencies, by agency

Agency	Percentage of Investigators
NIEHS
NHLBI
NIAID
NICHD
Other NIH
CDC
AHRQ
FDA
EPA
HUD
NSF
Other US government (not listed above)

Table 15. Community Partnership Outputs (Response options will be created based on feedback to open-ended questions).

Community Partnership Output			Number of Investigators	Percentage of Projects

Table 16. Percentage of investigators who believe research has had or may have future impacts in the next 10 years by impact area

Impact Area	Percentage of Investigators
	Current Impact	Future Potential Impact
greater understanding of the selected science portfolio’s disease mechanisms
greater understanding of individual, social, and environmental factors associated with the selected science portfolio
improved environmental measurement techniques
increased evidence regarding effective interventions
improved environmental control techniques
to changes in curriculum for clinical/public health students
changes in curriculum for K-12 or families
changes in business practices regarding the selected science portfolio
changes in environmental standards or regulations for the selected science portfolio
changes in public health/environmental legislation related to asthma
changes in clinical guidelines for the selected science portfolio
changes in clinical practice relevant to the selected science portfolio
changes in public knowledge and practices related to the selected science portfolio prevention and control
increased public advocacy for the selected science portfolio prevention and control

Table 12. Percentage of investigators who believe research has had impacts by impact area and by NIEHS funding status

Impact Area	Percentage of Investigators
	No NIEHS funding	NIEHS funding	NIEHS funding primary
greater understanding of the selected science portfolio disease mechanisms
greater understanding of individual, social, and environmental factors associated with the selected science portfolio
improved environmental measurement techniques
increased evidence regarding effective interventions
improved environmental control techniques
changes in curriculum for clinical/public health students
changes in curriculum for K-12 or families
changes in business practices regarding the selected science portfolio
changes in environmental standards or regulations for the selected science portfolio
changes in public health/environmental legislation related to the selected science portfolio
changes in clinical guidelines for the selected science portfolio
changes in clinical practice relevant to the selected science portfolio
changes in public knowledge and practices related to the selected science portfolio prevention and control
increased public advocacy for the selected science portfolio prevention and control